Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2024 | Story Anthony Mthembu | Photo Tania Allan
Business School 25 Year Celebration
Some of the guests and staff members of the UFS Business School who attended the 25th anniversary celebration of the school.

To commemorate its 25th anniversary, the Business School at the University of the Free State (UFS) held a celebratory event on the UFS Bloemfontein Campus on 22 November 2024.

Prof Frans Prinsloo, acting Dean of the Faculty of Economic and Management Sciences (EMS) at the UFS who attended the event, said, “The occasion is not just a celebration of the passing of time, but it’s also an opportunity for us to reflect on the values, achievements, and aspirations that have shaped the journey of the UFS Business School.” The event, which was regarded as a ‘momentous milestone’, was also attended by Prof Nicolene Barkhuizen, Director of the UFS Business School, Prof Frederick Fourie and Prof Bennie Anderson – founding members of the Business School, as well as Prof Tienie Crous and Prof Hendri Kroukamp, who are former deans of EMS.

A walk down memory lane

In his opening address, Prof Prinsloo reflected on the growth of the Business School over the past 25 years and highlighted some of the achievements of the staff that make up the Business School. However, the highlight of the event for many in the audience was the trip down memory lane by the founding members of the Business School as well as the former deans of the faculty.

 In their address, Profs Fourie and Anderson shared some of their fondest memories and experiences as they worked towards putting together the Business School. For instance, Prof Fourie indicated that in order to ensure that the syllabus was of high quality, the founding members had to travel overseas and learn from several institutions, such as Harvard Business School.

In addition, Profs Fourie and Anderson spoke extensively about their pride in the Business Management and Leadership (BML) programme, offered by the Business School. According to Prof Fourie, the degree was the brainchild of Prof Anderson, who for several reasons wanted to consider working adults who might not have had experience in school learning. As such, they consider the BML programme as one of their most special achievements, given its impact. Furthermore, Prof Crous and Prof Kroukamp also shared their memories of being part of the institution, and specifically the Business School.

Forging ahead for another 25 years

In the pursuit of 25 more years, Prof Barkhuizen indicated that the school is aiming to achieve success with several projects. These include staff and student exchanges in order to optimise the experience of both stakeholders. “Even though we have a global reach, it is important for us to apply it locally,” she said. In addition, Prof Barkhuizen highlights that for the Business School to continue serving the needs of its unique student clientele, it needs to become more agile. As such, it will continuously reinvent its programmes with the input of its stakeholders. For instance, she indicated that the school is looking at implementing joint qualification offerings, among other things.

As the event ended, Prof Barkhuizen said that she was, “so proud of the progress made by the Business School; it has been a journey to get here, but this function today taught me to never give up hope and not to give up on one’s dreams”.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept